| Autor: |
Tudurachi BS; Internal Medicine Department, 'Grigore T. Popa' University of Medicine and Pharmacy, 700503 Iasi, Romania.; Cardiology Department, Cardiovascular Diseases Institute 'Prof. Dr. George I. M. Georgescu', 700503 Iasi, Romania., Anghel L; Internal Medicine Department, 'Grigore T. Popa' University of Medicine and Pharmacy, 700503 Iasi, Romania.; Cardiology Department, Cardiovascular Diseases Institute 'Prof. Dr. George I. M. Georgescu', 700503 Iasi, Romania., Tudurachi A; Cardiology Department, Cardiovascular Diseases Institute 'Prof. Dr. George I. M. Georgescu', 700503 Iasi, Romania., Sascău RA; Internal Medicine Department, 'Grigore T. Popa' University of Medicine and Pharmacy, 700503 Iasi, Romania.; Cardiology Department, Cardiovascular Diseases Institute 'Prof. Dr. George I. M. Georgescu', 700503 Iasi, Romania., Zanfirescu RL; Cardiology Department, Cardiovascular Diseases Institute 'Prof. Dr. George I. M. Georgescu', 700503 Iasi, Romania.; Physiology Department, 'Grigore T. Popa' University of Medicine and Pharmacy, 700503 Iasi, Romania., Stătescu C; Internal Medicine Department, 'Grigore T. Popa' University of Medicine and Pharmacy, 700503 Iasi, Romania.; Cardiology Department, Cardiovascular Diseases Institute 'Prof. Dr. George I. M. Georgescu', 700503 Iasi, Romania. |
| Abstrakt: |
Myocardial infarction (MI) often leads to heart failure (HF) through acute or chronic maladaptive remodeling processes. This establishes coronary artery disease (CAD) and HF as significant contributors to cardiovascular illness and death. Therefore, treatment strategies for patients with CAD primarily focus on preventing MI and lessening the impact of HF after an MI event. Myocardial fibrosis, characterized by abnormal extracellular matrix (ECM) deposition, is central to cardiac remodeling. Understanding these processes is key to identifying new treatment targets. Recent studies highlight SGLT2 inhibitors (SGLT2i) and GLP-1 receptor agonists (GLP1-RAs) as favorable options in managing type 2 diabetes due to their low hypoglycemic risk and cardiovascular benefits. This review explores inflammation's role in cardiac fibrosis and evaluates emerging anti-diabetic medications' effectiveness, such as SGLT2i, GLP1-RAs, and dipeptidyl peptidase-4 inhibitors (DPP4i), in preventing fibrosis in patients with diabetes post-acute MI. Recent studies were analyzed to identify effective medications in reducing fibrosis risk in these patients. By addressing these areas, we can advance our understanding of the potential benefits of anti-diabetic medications in reducing cardiac fibrosis post-MI and improve patient outcomes in individuals with diabetes at risk of HF. |
